In a move that could prove crucial to ensuring Australia’s vaccine against the vaccine-preventable disease, a federal government-funded study has found a solution to an allergy to polyethylenes, the substance that gives the polymer its distinctive smell.
The study, funded by the Australian government, was published today in the Journal of the Australian Medical Association.
“Our work is the first to demonstrate that a solution of polyethylenediaminetetra-3-ol (PEG-3) can be used to reduce the incidence of anaphylaxis to polymers,” Dr James Kastel, an allergist and immunologist from the University of New South Wales in Sydney, said in a statement.
“This finding represents a significant advance in immunotherapy, potentially giving people with allergies to polyphenols the best chance of a successful immunotherapy.”
Dr Kastels work is described in the study as a “gold standard” in the field of immunotherapy.
He said it had the potential to be used for a variety of different conditions, including allergic conditions, and that the drug could also be used in the treatment of non-allergic conditions such as asthma and rheumatoid arthritis.
A trial involving 1,600 people with anaphysias who had been in the control group of a trial in which they were given a placebo for a week had been completed, Dr Kestel said.
It was hoped that the study would pave the way for a larger trial of the drug to see if it could reduce the prevalence of an allergy.
Dr Kests study has shown that, when used as directed, the PEG-1 inhibitors polyethylenoic acid (PEOA) and polyethyl-2-butadiene-1-acetate (PETAA) reduced the incidence rate of an allergic reaction to a single peptide (the antibody to the antigen) by an average of 40 per cent, compared to placebo.
Dr Michael Hargreaves, a research fellow at the University Of Sydney, told news.com.au that this study had a “potential to be a game changer for the immunotherapy market” and suggested that a drug of this type should be considered in people with “very severe or severe allergies”.
“It’s important to recognise that the treatment has only been tested in a small number of people with a very severe allergy and that there are some patients with a milder allergic reaction that are also being treated with PEOA and PETAA,” he said.
“In other words, we still need to test the drug in a larger number of patients, and we need to see whether it works well.”
“We don’t yet know whether PEOAs and PETAs will be effective in preventing severe or mild reactions to the vaccine, but we do know that we can reduce the severity of an attack in a much shorter period of time than using a placebo.”
He said that a vaccine of this nature was also promising in terms of safety.
“If it’s effective in the small number [of people with severe or moderate allergy] who are being treated, it’s important that we get the drug into those patients as soon as possible to make sure it’s safe for them,” he told news “The idea is that we might eventually get a vaccine that will reduce the rate of reactions that people are suffering.”
Dr Hargneas study was also published as part of a larger study which looked at a treatment for the vaccine in a group of people who had a severe allergic reaction.
The vaccine was given to a group that were given the vaccine for only six months, and the researchers looked at the number of reactions, the duration of the response, and other data.
The results showed that the vaccine was safe and effective.
“The safety profile of the vaccine is excellent and it seems to be well tolerated,” Dr Hestlays lead author, Dr Ramesh Shah, said.
A vaccine that reduces the frequency of allergies Dr Shah said that the idea was that it would eventually be possible to produce a vaccine in which the antibodies produced in the vaccination would prevent anaphanasias in a smaller number of individuals.
“It would be a very powerful vaccine, it would be safe, and it would have an effective efficacy,” he explained.
“But we are very far away from that now.”
Dr Shah told newscom.ae that there were “no clinical data” on the vaccine currently being tested in Australia, and would not be able to provide any data to support the claims of the study until after it was completed.
“We have been working with the Australian Food and Drug Administration for a number of years and we are awaiting their approval to begin trials,” he added.
Dr Harker Haughton, an allergy expert from the Queensland University of Technology, said that if the research was successful, it could be used as a treatment in the future for